#HVO hVIVO PLC – >£5 million CRS contracts signed November 20, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its German subsidiary CRS, has signed contracts worth over £5 million since September. The early-phase clinical trial service contracts have been signed with five clients, including two returning mid-sized German pharma customers reaffirming CRS’ strong reputation and long-standing relationships in Germany. These pharma partnerships, given their volume and consistency, strengthens the Group’s sales pipeline…

#HVO hVIVO PLC – Trading Update and Acquisition January 29, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist early-stage drug development contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides an unaudited trading update for the year ended 31 December 2024. Highlights · Revenue up 11.9% to £62.7 million (2023: £56.0 million) · EBITDA margin of c.26% (2023: 23.3%) · Cash of £44.2 million as at 31 December 2024 (31 December 2023: £37.0 million)…

#HVO hVIVO PLC – hMPV challenge model update January 13, 2025 – Posted in: hVIVO (HVO)

Highlights · hVIVO successfully completes pilot hMPV characterisation study · Study exhibited strong infectivity rate and induced symptomatic disease in healthy volunteers · Now marketing for hMPV challenge trials to support the development of hMPV vaccines and antivirals · Dr Andrew Catchpole to present data from the study at the 13th International RSV Symposium in Brazil hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and…

#HVO hVIVO PLC – COVID-19 study published in Nature Communications December 12, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that an additional peer-reviewed paper from the world’s first COVID-19 characterisation trial has been published in Nature Communications. “SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections”, by Rosenheim, J. et al. is available in Nature Communications,…

#HVO hVIVO PLC – Long Term Incentive Plan/ PDMR Notification October 11, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that the Company has granted Yamin Khan, the Company’s Chief Executive Officer, and certain senior employees, a Long Term Incentive Plan (“LTIP”). The awards are intended to reward, incentivise and retain Mr Khan and certain senior employees to deliver sustainable growth for shareholders. Under the LTIP, Mr Khan has…

#HVO hVIVO PLC – Euronext cancellation August 5, 2024 – Posted in: hVIVO (HVO), Vela Technologies Plc (VELA)

hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its intention to cancel its admission (“the Cancellation”) to trading on Euronext Growth. As hVIVO’s primary operations, along with the majority of its employees and investor base, are in the UK, the Board has decided to consolidate trading of the Company’s stock to its primary…

#HVO hVIVO PLC – Long Term Incentive Plan / PDMR Notification February 15, 2024 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that the Company has granted options to Stephen Pinkerton, Chief Financial Officer, under its Long Term Incentive Plan (“LTIP”). The LTIP has been designed to reward, incentivise and retain Mr Pinkerton to deliver sustainable growth for shareholders. Under the rules of the LTIP, the…

#HVO hVIVO PLC – Proposed Secondary Placing of Ordinary Shares February 14, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has been informed by certain Directors of the Company of their intention to sell, in aggregate, not less than 14,000,000 ordinary shares of 0.1 pence each (“Ordinary Shares”) in the capital of Company (the “Placing Shares”), representing approximately 25% of their current shareholding, at a price of 28 pence per Placing…

#HVO hVIVO PLC – £16.8m RSV contract & Trading ahead of guidance December 13, 2023 – Posted in: Blog, hVIVO (HVO)

£16.8m full-service RSV contract with top five global pharma client Highlights · Pharma client is funding expedited manufacture of additional supply of RSV challenge agent · Confirmatory challenge cohort to verify infectivity of the new RSV challenge virus batch · Multiple cohort challenge trial to test efficacy of client’s RSV antiviral candidate · Trading ahead of previous market expectations driven by margin expansion hVIVO plc (AIM & Euronext: HVO), the world leader in testing…

#HVO hVIVO PLC – Positive results from flu human challenge study October 5, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Pneumagen, a clinical-stage biotech company, reporting successful clinical proof of concept for its broad-spectrum antiviral candidate Neumifil, demonstrated from a Phase 2a influenza human challenge study conducted by hVIVO. The randomised, double-blind, placebo-controlled study enrolled 104 healthy adult volunteers, recruited through the FluCamp platform, and evaluated two dose regimens…